[1] Adega F, Borges A, Chaves R. Cat mammary tumors: Genetic models for the human counterpart. Vet Sci 2016; 3(3). https://doi.org/10.3390/vetsci3030017.
[2] Edechi C, Ikeogu N, Uzonna J, Myal Y. Regulation of Immunity in Breast Cancer. Cancers (Basel) 2019; 11(8):1080. https://doi.org/10.3390/cancers11081080.
[3] Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005; 4(4):1123–33. https://doi.org/10.1021/pr0500814.
[4] Kabel AM. Tumor markers of breast cancer: New prospectives. J Oncol Sci 2017; 3(1):5–11. https://doi.org/10.1016/j.jons.2017.01.001.
[5] Zaenker P, Gray ES, Ziman MR. Autoantibody Production in Cancer-The Humoral Immune Response toward Autologous Antigens in Cancer Patients. Autoimmun Rev 2016; 15:477–83. https://doi.org/10.1016/j.autrev.2016.01.017.
[6] Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Türeci O, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008; 63(3):228–33. https://doi.org/10.1136/thx.2007.083592.
[7] Xia J, Shi J, Wang P, Song C, Wang K, Zhang J, et al. Tumour-Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta-Analysis. Scand J Immunol 2016; 83(6):393–408. https://doi.org/10.1111/sji.12430.
[8] Qiu J, Keyser B, Lin ZT, Wu T. Autoantibodies as potential biomarkers in breast cancer. Biosensors 2018; 8(3):67. https://doi.org/10.3390/bios8030067.
[9] Banin Hirata BK, Oda JMM, Losi Guembarovski R, Ariza CB, Oliveira CEC De, Watanabe MAE. Molecular markers for breast cancer: Prediction on tumor behavior. Dis Markers 2014. https://doi.org/10.1155/2014/513158.
[10] Gendler SJ. MUC1, The renaissance molecule. J Mammary Gland Biol Neoplasia 2001; 6(3):339–53. https://doi.org/10.1023/A:1011379725811.
[11] Tansey WP. Mammalian MYC Proteins and Cancer. New J Sci 2014; 2014:1–27. https://doi.org/10.1155/2014/757534.
[12] Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, et al. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br J Cancer 2016; 114(8):917–28. https://doi.org/10.1038/bjc.2016.46.
[13] ELSTON CW, ELLIS IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up. Histopathology 1991; 19(5):403–10. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x.
[14] Ali MRK, Ibrahim IM, Ali HR, Selim SA, El-Sayed MA. Treatment of natural mammary gland tumors in canines and felines using gold nanorods-assisted plasmonic photothermal therapy to induce tumor apoptosis. Int J Nanomedicine 2016; 11:4849–63. https://doi.org/10.2147/IJN.S109470.
[15] Ali MR, Farghali HA, Ali HR, Osman AH, Soliman YA, Wu Y, et al. Abstract 175: Combination of plasmonic photothermal therapy with surgery applied to naturally occurring mammary tumors in canines and felines: clinical outcomes and molecular studies. Cancer Res., vol. 77, American Association for Cancer Research (AACR); 2017, p. 175–175. https://doi.org/10.1158/1538-7445.am2017-175.
[16] Edechi C, Ikeogu N, Uzonna J, Myal Y. Regulation of Immunity in Breast Cancer. Cancers (Basel) 2019; 11(8):1080. https://doi.org/10.3390/cancers11081080.
[17] Liu Y, Liao Y, Xiang L, Jiang K, Li S, Huangfu M. A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with breast cancer. Int J Clin Oncol 2016; 22(2):291-296. https://doi.org/10.1007/s10147-016-1047-0.
[18] Ali MRK, Farghali HAM, Wu Y, El-Sayed I, Osman AH, Selim SA, et al. Gold Nanorod-Assisted Photothermal Therapy Decreases Bleeding during Breast Cancer Surgery in Dogs and Cats. Cancers (Basel) 2019; 11(6):851. https://doi.org/10.3390/cancers11060851.
[19] Farghali HA, AbdElKader NA, Khattab MS, AbuBakr HO. Novel approach to gastric mucosal defect repair using fresh amniotic membrane allograft in dogs (experimental study). Stem Cell Res Ther 2017; 8(1):235. https://doi.org/10.1186/s13287-017-0682-3.
[20] Tankaew P, Singh-La T, Titaram C, Punyapornwittaya V, Vongchan P, Sawada T, et al. Evaluation of an In-house indirect ELISA for detection of antibody against haemorrhagic septicemia in Asian elephants. J Microbiol Methods 2017; 134:30–34. https://doi.org/10.1016/j.mimet.2017.01.008.
[21] Tankaew P, Srisawat W, Singhla T, Tragoolpua K, Kataoka Y, Sawada T, et al. Comparison of two indirect ELISA coating antigens for the detection of dairy cow antibodies against Pasteurella multocida. J Microbiol Methods 2018; 145:20–7. https://doi.org/10.1016/j.mimet.2017.12.005.
[22] Poolperm P, Varinrak T, Kataoka Y, Tragoolpua K, Sawada T, Sthitmatee N. Development and standardization of an in-house indirect ELISA for detection of duck antibody to fowl cholera. J Microbiol Methods 2017; 142:10–14. https://doi.org/10.1016/j.mimet.2017.08.018.
[23] Näslund K, Blomqvist G, Vernersson C, Zientara S, Bréard E, Valarcher JF. Development and evaluation of an indirect enzyme-linked immunosorbent assay for serological detection of Schmallenberg virus antibodies in ruminants using whole virus antigen. Acta Vet Scand 2014; 56:71. https://doi.org/10.1186/s13028-014-0071-1.
[24] https://www.ncbi.nlm.nih.gov/protein/P41685.1
[25] https://www.ncbi.nlm.nih.gov/protein/XP_023103255.1
[26] https://www.ncbi.nlm.nih.gov/protein/P68271.1
[27] https://www.ncbi.nlm.nih.gov/protein/XP_003983789.1
[28] Wang P, Qin J, Ye H, Li L, Wang X, Zhang J. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer. J Cell Biochem 2019; 120(3):3091–3100. https://doi.org/10.1002/jcb.27497.
[29] Jin Y, Kim SC, Kim HJ, Ju W, Kim YH, Kim HJ. Use of autoantibodies against tumor-associated antigens as serum biomarkers for primary screening of cervical cancer. Oncotarget 2017; 8(62):105425–105439. https://doi.org/10.18632/oncotarget.22231.
[30] Liu W, De La Torre IG, Gutiérrez-Rivera MC, Wang B, Liu Y, Dai L, et al. Detection of autoantibodies to multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Tumor Biol 2015; 36(2):1307–12. https://doi.org/10.1007/s13277-014-2756-5.
[31] Ye H, Sun C, Ren P, Dai L, Peng B, Wang K, et al. Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Oncol Lett 2013; 5:663–8. https://doi.org/10.3892/ol.2012.1062.
[32] Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri SJ, et al. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res 2012; 5(8):1036–1043. https://doi.org/10.1158/1940-6207.CAPR-11-0558.
[33] Hsu T-C, Tsay GJ, Chen T-Y, Liu Y-C, Tzang B-S. Anti-PCNA autoantibodies preferentially recognize C-terminal of PCNA in patients with chronic hepatitis B virus infection. Clin Exp Immunol 2006; 144(1):110–116. https://doi.org/10.1111/j.1365-2249.2006.03046.x.
[34] Zhang J, Casiano C, Peng X, Koziol J, Chan E, Tan E. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003; 12(2):136-43.
[35] Takasaki Y, Kogure T, Takeuchi K, Kaneda K, Yano T, Hirokawa K, et al. Reactivity of Anti-Proliferating Cell Nuclear Antigen (PCNA) Murine Monoclonal Antibodies and Human Autoantibodies to the PCNA Multiprotein Complexes Involved in Cell Proliferation. J Immunol 2001; 166(7):4780–4787. https://doi.org/10.4049/jimmunol.166.7.4780.
[36] Tzang BS, Chen TY, Hsu TC, Liu YC, Tsay GJ. Presentation of autoantibody to proliferating cell nuclear antigen in patients with chronic hepatitis B and C virus infection. Ann Rheum Dis 1999; 58(10):630–634. https://doi.org/10.1136/ard.58.10.630.
[37] Crowther JR. ELISA. Theory and practice. Methods Mol Biol 1995; 42:1–218. https://doi.org/10.1385/0-89603-279-5:1.
[38] Gordis L. Assessing the validity and reliability of diagnostic and screening tests. In: Gordis L, editor. Epidemiology. 2nd ed. Philadelphia: Saunders; 2000. p. 63–81.
[39] SAS. (2013). The SAS system for Windows, release 9.4. In Cary, North Carolina, USA: SAS Institute Inc.
[40] Lacombe J, Mangé A, Solassol J. Use of Autoantibodies to Detect the Onset of Breast Cancer. J Immunol Res 2014; 2014. https://doi.org/10.1155/2014/574981.
[41] Tan HT, Low J, Lim SG, Chung MCM. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009; 276(23):6880–6904. https://doi.org/10.1111/j.1742-4658.2009.07396.x.
[42] Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, et al. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. Br J Cancer 2017; 116(4):501–508. https://doi.org/10.1038/bjc.2016.433.
[43] Ye X, Ling B, Xu H, Li G, Zhao X, Xu J, et al. Clinical significance of high expression of proliferating cell nuclear antigen in non-small cell lung cancer. Medicine (Baltimore) 2020; 99(16):e19755. https://doi.org/10.1097/MD.0000000000019755.
[44] Malkas LH, Herbert BS, Abdel-Aziz W, Dobrolecki LE, Liu Y, Agarwal B, et al. A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc Natl Acad Sci U S A 2006; 103(51):19472–19477. https://doi.org/10.1073/pnas.0604614103.
[45] Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008; 452(7187):571–579. https://doi.org/10.1038/nature06916.
[46] Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, et al. Autoantibodies in breast cancer: Their use as an aid to early diagnosis. Ann Oncol 2007; 18(5):868–73. https://doi.org/10.1093/annonc/mdm007.
[47] Evans RL, Pottala J V., Nagata S, Egland KA. Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality. BMC Cancer 2018; 18(1):1–9. https://doi.org/10.1186/s12885-018-4022-5.
[48] Yilmaz MT, Elmali A, Yazici G. Abscopal Effect, From Myth to Reality: From Radiation Oncologists’ Perspective. Cureus 2019; 11(1): e3860. https://doi.org/10.7759/cureus.3860.
[49] Suppiah A, Greenman J. Clinical utility of anti-p53 auto-antibody: Systematic review and focus on colorectal cancer. World J Gastroenterol 2013; 19(29):4651–4670. https://doi.org/10.3748/wjg.v19.i29.4651.
[50] Zalcman G, Schlichtholz B, Trédaniel J, Urban T, Lubin R, Dubois I, et al. Monitoring of p53 autoantibodies in lung cancer during therapy: Relationship to response to treatment. Clin Cancer Res 1998; 4(6):1359–1366.
[51] Takeda A, Shimada H, Nakajima K, Imaseki H, Suzuki T, Asano T, et al. Monitoring of p53 autoantibodies after resection of colorectal cancer: Relationship to operative curability. Eur J Surg 2001; 167(1):50–53. https://doi.org/10.1080/110241501750069828.
[52] Firestein G, Budd R, Gabriel S E McInnes I B and O'Dell J. Kelley’s Textbook of Rheumatology - 9th Edition. Elsevier 2013. https://www.elsevier.com/books/kelleys-textbook-of-rheumatology/9781437717389.
[53] Azami A, Suzuki N, Azami Y, Seto I, Sato A, Takano Y, et al. Abscopal effect following radiation monotherapy in breast cancer: A case report. Mol Clin Oncol 2018; 9(3):283–286. https://doi.org/10.3892/mco.2018.1677.